Forbion leads £35 million (c.$43 million) Series A financing in LoQus23 Therapeutics to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease

(October 2, 2024) in Portfolio News.

• Financing led by Forbion with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF)
• Lead programme targeting MutSβ set to enter the clinic in 2026, offering a potentially disease-modifying therapy for Huntington’s disease
• Forbion General Partner Rogier Rooswinkel joins Board of Directors